SBIR/STTR Research Award
VesiVax HIVgp41e Vaccine Design
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R1JMHFESEKD5
- Solicitation number
- PHS-2022-1
- Topic code
- 101
Research abstract
To engineer novel HIV gp41 ectodomain antigens for the incororation into the immunogenic VesiVax formulations.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- High bandwidth all-optical electrophysiology
- Fast multicolor confocal fluorescence imager for neural network mapping
- Advanced culture and recording system for long-term electrophysiological profiling in human brain organoids
- Commercialization Readiness for a Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging
- Design and Development of an Advanced Functional MRI Software as Medical Device (SaMD) forClinical Trials and Therapeutic Applications in Neuropsychiatry
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense